Tbilisi

Tbilisi is rapidly emerging as a premier life sciences hub in the Caucasus, distinguished by its strategic position as a bridge between European and Asian markets.

The city is best known for its streamlined regulatory framework, which offers a competitive fast-track registration process for pharmaceuticals and medical devices already approved by the FDA or EMA.

This efficiency has catalyzed a robust pharmaceutical manufacturing sector, with local and international players leveraging Georgia's "tax-free" regimes to export high-quality generic medicines globally.

In biotechnology, Tbilisi is gaining international recognition for its pioneering work in bacteriophage therapy, housing world-renowned research institutes that lead the fight against antibiotic resistance.

The city’s healthcare innovation is further bolstered by a highly privatized hospital network, driving significant demand for cutting-edge medical devices and digital health solutions.

Academic research remains a cornerstone of the ecosystem, with institutions like Ilia State University and Tbilisi State Medical University fostering a steady pipeline of skilled biomedical talent.

Furthermore, Tbilisi has become a "go-to" destination for clinical trials, offering sponsors diverse patient demographics, cost-effective operations and rapid ethical committee approvals.

As biotech startups and contract research organizations (CROs) increasingly gravitate toward the city, Tbilisi is solidifying its reputation as a center for precision medicine and specialized therapeutic development.